Rosiglitazone disrupts pancreatic ductal adenocarcinoma progression by activating the tumor suppressor ESE3/EHF

Schematic depiction of the roles of the tumor suppressor ESE3/EHF in PDAC. (A) ESE3/EHF inhibits PDAC metastasis through direct transcriptional upregulation of E-cadherin expression in PDAC¹⁶. (B) ESE3/EHF decreases tumor-infiltrating T reg cells and MDSCs through transcriptional suppression of the expression of TGFβ1 and GM-CSF¹⁷. (C) ESE3/EHF is a tumor cell-intrinsic and tumor cell-extrinsic master transcription factor that disrupts the crosstalk between CSCs and their PSC-derived CSC-supportive niche by negatively regulating tumor CXCR4. Targeting ESE3/EHF by rosiglitazone provides an alternative strategy to induce PDAC regression¹¹.